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Abstract: Hepatitis C virus (HCV) remains a major public health
problem, affecting approximately 130 million people worldwide.
HCV infection can lead to cirrhosis, hepatocellular carcinoma, and
end-stage liver disease, as well as extrahepatic complications such
as cryoglobulinemia and lymphoma. Preventative and therapeutic
options are severely limited; there is no HCV vaccine available, and
nonspeciﬁc, IFN-based treatments are frequently ineffective. Develop-
ment of targeted antivirals has been hampered by the lack of robust
HCV cell culture systems that reliably predict human responses. Here,
we show the entire HCV life cycle recapitulated in micro-patterned
co-cultures (MPCCs) of primary human hepatocytes and supportive
stroma in a multiwell format. MPCCs form polarized cell layers
expressing all known HCV entry factors and sustain viral replication
for several weeks. When coupled with highly sensitive ﬂuorescence-
and luminescence-based reporter systems, MPCCs have potential as
a high-throughput platform for the simultaneous assessment of
in vitro efﬁcacy and toxicity proﬁles of anti-HCV therapeutics.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
With an estimated 170 million infected individuals, hepatitis C
virus (HCV) has a major impact on public health. The majority of
HCV-infected individuals develop chronic hepatitis that mayJournal of Hepatology 20
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In recent years, tremendous progress has been made in deci-
phering HCV–host cell interactions. The establishment of novel
and robust infectious model systems has allowed for detailed
study of the entire HCV life cycle in vitro [1]. However, thesemodel
systems rely on unique HCV isolates (i.e. JHF1) and on speciﬁc cell
lines (i.e. Huh7) for a reproducible and standardized analysis of
HCV–host cell interactions. In vivo, the hepatocyte is the primary
target cell of HCV. The liver’s architecture is elaborate and hepato-
cytes are characterized by a complex and highly-polarized mor-
phology [2]. Human hepatoma cells differ from primary human
hepatocytes (PHH)with respect tomorphology, proliferation, gene
expression, and innate immune responses but arewidely used as a
surrogate model for human hepatocytes because PHH are difﬁcult
to maintain in cell culture and infection with recombinant or
serum-derived HCV is not robust. Indeed, PHH do not proliferate
and tend to rapidly loose their phenotype and viability upon isola-
tion. Therefore, innovative strategies that circumvent these draw-
backs and improve PHH culture are needed. Furthermore, a PHH-
based HCV infectious model system would be of great interest to
determine the efﬁcacy and toxicity of novel antivirals. Interest-
ingly, transgenic immunodeﬁcient mice with hepatocyte-lethal
phenotype have been successfully transplanted with PHH and
are susceptible to HCV infection [3,4]. In the transplanted mice,
PHH may occupy the majority of the liver parenchyma and pre-
serve their phenotype for several months, suggesting that the
in vivo microenvironment stabilizes the PHH phenotype.
In the past years, tissue engineering has greatly improved PHH
culture conditions in order to preserve and modulate PHH pheno-
type.Micro-patternedco-culture (MPCC)of PHHwithmouseﬁbro-
blasts (3T3-J2 cells) (Fig. 1) stabilizes the PHH phenotype (e.g.
synthesis of albumin, urea, and cytochrome P450 activity) for sev-
eral weeks and has been proposed as a model to study drug safety
[5]. This model appears robust as stabilization of liver functions
was observed with both fresh and cryopreserved PHH from differ-
ent donors. Of note, like in monoculture, PHH do not seem to pro-
liferate under MPCC culture conditions. On the other hand,
virologists have been continuously trying to improve the HCV
models andmost recently two highly sensitive new reportermod-
elsweredescribed [6]: anHCVcc reportervirusexpressing secreted
Gaussia luciferase (Jc1FLAG2(p7-nsGluc2A) and a ﬂuorescent10 vol. 53 j 388–389
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Fig. 1. Microscale primary human hepatocyte co-cultures to study hepatitis C
virus (HCV) infection. Schematic representation of micro-patterned co-cultures
(MPCC) of primary human hepatocytes (PHH) for the study of HCV infection. (A) A
polydimethylsiloxane (PDMS) stencil consisting of membranes with through-
holes is applied at the bottom of cell culture wells. (B) A solution of collagen is
then added to the wells to allow collagen to adsorb to the substrate via the
through-holes. (C) Micro-patterned collagen is left on the substrate upon stencil
removal. (D) PHH are seeded in the wells and selectively adhere to collagen-
coated domains. (E) Subsequently, mouse embryonic ﬁbroblasts (3T3-J2) are
seeded into the remaining bare areas as feeder cells. (F) This generates MPCC PHH
co-cultures. (G) PHH may be transduced with a ﬂuorescent RFP-NLS-IPS reporter
to visualize serum-derived HCV or recombinant cell culture-derived HCV (HCVcc)
infection of PHH. HCV infection is indicated by nuclear translocation of the
reporter. (H) Alternatively, Gaussia luciferase reporter viruses may be used to
study HCVcc infection of PHH. Infection is detected by quantitation of luciferase
secretion into cell culture supernatants.
JOURNAL OF HEPATOLOGYprotein (EGFP or RFP) reporter containing an HCV protease cleav-
age site (IPS-1). In contrast to current model systems, these new
reporter systems offer the advantage of determiningHCV infection
in living cells without the need for cell lysis (Fig. 1).
Combining these two advancements, the Rice laboratory
established a new model system to study persistent HCV infec-
tion in PHH [7]. Interestingly, MPCC PHH appear to polarize [7]
and HCV host entry factor distribution seems to be comparable
to liver hepatocytes [8]. Thus, MPCC PHH appear to reﬂect hepa-
tocyte morphology in the liver more closely than PHH monocul-
ture or hepatoma cells. Noteworthy, MPCC PHH were able to
replicate HCV for 2 weeks as shown by luciferase secretion that
was reduced in the presence of HCV polymerase and protease
inhibitor [7]. In addition, expression of the ﬂuorescent reporter
RFP-NLS-IPS allowed for the assessment of replication of cell cul-Journal of Hepatology 201ture and serum-derived HCV at a single cell level. Importantly, in
line with previous results obtained in hepatoma cells, antibodies
directed against CD81 and HCV E2 inhibited HCV infection. Of
note, MPCC PHH are able to support the entire HCV lifecycle as
supernatants from infected MPCC PHH were infectious in hepa-
toma cells [7]. Although HCV infection and viral spread occurred
only in a small fraction of cells, MPCC PHH appear to be a valuable
and robust model system to study HCV infection in primary cells.
The possibility to use ﬂuorescent reporter proteins in MPCC
PHH broadens the scope of this model system as it will allow
for studying HCV infection of a large panel of genotypes and iso-
lates without engineering reporter viruses. Moreover, as HCV
associates with lipoproteins in vivo and this impacts viral entry
and neutralization [9,10], it will be of interest to compare infec-
tious virions released from MPCC and hepatoma cells with
respect to biochemical properties, host factor usage, infectivity,
and neutralization. Furthermore, this model also offers a unique
opportunity to assess the efﬁcacy of novel antivirals but also to
determine drug interactions and toxicity in HCV-infected cells [7].
In conclusion, this original model system based on the natural
host cell of HCV infection clearly provides an important step for-
ward for the understanding of virus–host interactions in the
HCV-infected liver.
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